Concepedia

Author

Jörg J. Möhrle

Medicines for Malaria Venture

Also Known As

Jörg J Möhrle, Jörg J. MÖHRLE, Jörg J. Möhrle, Jörg Möhrle, Möhrle, Jörg, Parmar, Deven

70

Publications

3.6K

Citations

31

H-Index

25

Concepts

All Affiliations

Medicines for Malaria VentureQIMR Berghofer Medical Research InstituteThe University of QueenslandQ-PharmMater Health Services
JJ

About

Jörg J. Möhrle is an author at Medicines for Malaria Venture specializing in malaria, medicine, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

476

2

Health Sciences

1

1

21

3

Natural Sciences

1

1

38

4

Biochemistry

1

1

38

5

Global Health

1

1

21

Jörg J. Möhrle

×

38

Publications

2.5K

Citations

28

H-Index

YearCitations

Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study

Alejandro Llanos‐Cuentas, Marcus Lacerda, Ronnatrai Rueangweerayut,

The Lancet

2013

242

Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial

Aung Pyae Phyo, Podjanee Jittamala, François Nosten,

The Lancet Infectious Diseases

2015

187

A Pilot Randomised Trial of Induced Blood-Stage Plasmodium falciparum Infections in Healthy Volunteers for Testing Efficacy of New Antimalarial Drugs

James McCarthy, Silvana Sekuloski, Paul Griffin,

PLoS ONE

2011

172

Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study

Alejandro Llanos‐Cuentas, Martín Casapía, Raúl Chuquiyauri,

The Lancet Infectious Diseases

2018

139

A controlled human malaria infection model enabling evaluation of transmission-blocking interventions

Katharine A. Collins, Claire Wang, Matthew Adams,

Journal of Clinical Investigation

2018

129

A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study

James McCarthy, Thomas Rückle, Elhadj Djeriou,

Malaria Journal

2016

125

Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study

James McCarthy, Julie Lotharius, Thomas Rückle,

The Lancet Infectious Diseases

2017

124

Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers

Ronnatrai Rueangweerayut, Germana Bancone, Emma J. Harrell,

American Journal of Tropical Medicine and Hygiene

2017

117

DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection

Mihály Sulyok, Thomas Rückle, Alexandra Roth,

The Lancet Infectious Diseases

2017

103

Efficacy of OZ439 (artefenomel) against early <i>Plasmodium falciparum</i> blood-stage malaria infection in healthy volunteers

James McCarthy, Mark Baker, Peter O’Rourke,

Journal of Antimicrobial Chemotherapy

2016

102

Page 1